Read + Share
. Erratum: Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients
With BRAF(V600)-Mutant Metastatic Non-Small-Cell Lung Cancer. J Clin Oncol 2023 Dec 5:JCO2302518. doi: 10.1200/JCO.23.02518.
PMID: 38051975
|
 |
|
. Erratum: Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients
With BRAF(V600)-Mutant Metastatic Non-Small-Cell Lung Cancer. J Clin Oncol 2023 Dec 5:JCO2302518. doi: 10.1200/JCO.23.02518.
PMID: 38051975
|
|
|
|